Toll Free: 1-888-928-9744

Congestive Heart Failure (Heart Failure) - Pipeline Review, H1 2016

Published: Mar 22, 2016 | Pages: 397 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Congestive Heart Failure (Heart Failure) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Congestive Heart Failure (Heart Failure) - Pipeline Review, H1 2016', provides an overview of the Congestive Heart Failure (Heart Failure) pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Congestive Heart Failure (Heart Failure), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Congestive Heart Failure (Heart Failure) and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Congestive Heart Failure (Heart Failure)
- The report reviews pipeline therapeutics for Congestive Heart Failure (Heart Failure) by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Congestive Heart Failure (Heart Failure) therapeutics and enlists all their major and minor projects
- The report assesses Congestive Heart Failure (Heart Failure) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Congestive Heart Failure (Heart Failure)

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Congestive Heart Failure (Heart Failure)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Congestive Heart Failure (Heart Failure) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 List of Tables 7 List of Figures 9 Introduction 10 Global Markets Direct Report Coverage 10 Congestive Heart Failure (Heart Failure) Overview 11 Therapeutics Development 12 Pipeline Products for Congestive Heart Failure (Heart Failure) - Overview 12 Pipeline Products for Congestive Heart Failure (Heart Failure) - Comparative Analysis 13 Congestive Heart Failure (Heart Failure) - Therapeutics under Development by Companies 14 Congestive Heart Failure (Heart Failure) - Therapeutics under Investigation by Universities/Institutes 20 Congestive Heart Failure (Heart Failure) - Pipeline Products Glance 21 Late Stage Products 21 Clinical Stage Products 22 Early Stage Products 23 Unknown Stage Products 24 Congestive Heart Failure (Heart Failure) - Products under Development by Companies 25 Congestive Heart Failure (Heart Failure) - Products under Investigation by Universities/Institutes 32 Congestive Heart Failure (Heart Failure) - Companies Involved in Therapeutics Development 34 Amgen Inc. 34 AnGes MG, Inc. 35 Angion Biomedica Corp. 36 ARCA biopharma, Inc. 37 Ascelegen Therapeutics, Inc. 38 Asklepios BioPharmaceutical, Inc. 39 Asterias Biotherapeutics, Inc. 40 Athersys, Inc. 41 Bayer AG 42 BEAT BioTherapeutics Corp. 43 BioCardia, Inc. 44 Bristol-Myers Squibb Company 45 Capricor Therapeutics, Inc. 46 Celyad SA 47 FibroGen, Inc. 48 GlaxoSmithKline Plc 49 Glucox Biotech AB 50 Heart Metabolics Limited 51 Hemostemix Ltd 52 Innopharmax Inc. 53 Jiangsu Hengrui Medicine Co., Ltd. 54 Juventas Therapeutics, Inc. 55 La Jolla Pharmaceutical Company 56 Laboratoires Pierre Fabre SA 57 Lee's Pharmaceutical Holdings Limited 58 Les Laboratoires Servier SAS 59 Lonestar Heart, Inc. 60 Mast Therapeutics, Inc. 61 Merck & Co., Inc. 62 Mesoblast Limited 63 MI.TO. Technology S.r.L. 64 miRagen Therapeutics, Inc. 65 Novartis AG 66 Nuo Therapeutics, Inc. 67 Ono Pharmaceutical Co., Ltd. 68 Palatin Technologies, Inc. 69 Pfizer Inc. 70 PharmaIN Corporation 71 PhaseBio Pharmaceuticals, Inc. 72 Pluristem Therapeutics Inc. 73 Quantum Genomics SA 74 Recardio GmbH 75 RedHill Biopharma Ltd. 76 Sanofi 77 Stealth BioTherapeutics Inc. 78 Stemedica Cell Technologies, Inc. 79 Target Heart Biotec Srl 80 Theravance Biopharma, Inc. 81 TiGenix NV 82 Torrent Pharmaceuticals Limited 83 Trevena, Inc. 84 U.S. Stem Cell, Inc. 85 UniQure N.V. 86 Vichem Chemie Research Ltd. 87 Vicore Pharma AB 88 Zensun (Shanghai) Sci & Tech Co., Ltd. 89 Congestive Heart Failure (Heart Failure) - Therapeutics Assessment 90 Assessment by Monotherapy Products 90 Assessment by Combination Products 91 Assessment by Target 92 Assessment by Mechanism of Action 97 Assessment by Route of Administration 101 Assessment by Molecule Type 103 Drug Profiles 105 (sacubitril + valsartan) - Drug Profile 105 AAVS-100A1 - Drug Profile 108 ACP-01 - Drug Profile 109 AdipoCell - Drug Profile 111 AdipoCell + MyoCell - Drug Profile 113 aladorian sodium - Drug Profile 114 ALD-201 - Drug Profile 116 AMG-986 - Drug Profile 117 ANG-4011 - Drug Profile 118 AntimiR-199a - Drug Profile 119 ARX-720 - Drug Profile 120 BAY-1067197 - Drug Profile 121 BBR-12 - Drug Profile 122 beperminogene perplasmid - Drug Profile 123 BNP-CHF - Drug Profile 128 bucindolol hydrochloride - Drug Profile 129 C-21 - Drug Profile 132 C3BSCQR-1 - Drug Profile 134 CAP-1002 - Drug Profile 136 carvedilol CR - Drug Profile 138 carvedilol phosphate CR - Drug Profile 139 cenderitide - Drug Profile 140 CLR-325 - Drug Profile 142 CM-1 - Drug Profile 143 CTX-101 - Drug Profile 145 CXL-1036 - Drug Profile 147 CXL-1427 - Drug Profile 148 Drug for Heart Failure - Drug Profile 149 Drug to Inhibit Calpain for Heart Failure - Drug Profile 150 Drug to Inhibit Phosphoinositide 3-Kinase Gamma for Heart Failure - Drug Profile 151 Drugs to Inhibit miR-425 for Hypertension and Heart Failure - Drug Profile 152 ECR-A1 - Drug Profile 153 elamipretide - Drug Profile 154 enalapril maleate - Drug Profile 156 F-373280 - Drug Profile 157 FG-6874 - Drug Profile 158 FG-8205 - Drug Profile 159 finerenone - Drug Profile 160 furosemide - Drug Profile 161 GDF-11 - Drug Profile 162 Gene Therapy to Activate Adenylate Cyclase Type 6 for Heart Failure - Drug Profile 163 Gene Therapy to Activate UCn 2 for Congestive Heart Failure - Drug Profile 164 Gene Therapy to Inhibit GRK2 for Heart Failure - Drug Profile 165 Gene Therapy to Inhibit Mef2 for Heart Failure - Drug Profile 166 Gene Therapy to Target mAKAPbeta for Heart Failure - Drug Profile 167 GSK-2798745 - Drug Profile 168 istaroxime - Drug Profile 169 ITD-1 - Drug Profile 171 ivabradine hydrochloride - Drug Profile 172 ivabradine hydrochloride SR - Drug Profile 173 JVS-100 - Drug Profile 174 KBP-5074 - Drug Profile 176 MGN-9103 - Drug Profile 177 milrinone ER - Drug Profile 178 MP-3167 - Drug Profile 179 MPC-150IM - Drug Profile 181 MyoCell - Drug Profile 183 MyoCell SDF-1 - Drug Profile 184 Neucardin - Drug Profile 185 NM-922 - Drug Profile 187 Oligonucleotides for Heart Failure - Drug Profile 188 omecamtiv mecarbil MR - Drug Profile 189 ONO-4232 - Drug Profile 192 PB-1046 - Drug Profile 193 Peptides to Inhibit MyBP-C/Myosin Interaction for Heart Failure - Drug Profile 195 perhexiline maleate - Drug Profile 196 PF-05285401 - Drug Profile 198 PHIN-1138 - Drug Profile 203 PL-3994 - Drug Profile 204 PLX-PAD - Drug Profile 206 poloxamer - Drug Profile 210 pyroglutaminated serpinin - Drug Profile 212 QGC-101 - Drug Profile 213 REC-02 - Drug Profile 214 Recombinant Protein for Congestive Heart Failure - Drug Profile 215 rivaroxaban - Drug Profile 216 RT-100 - Drug Profile 222 RT-110 - Drug Profile 223 RT-210 - Drug Profile 224 S-38844 - Drug Profile 225 SAR-296968 - Drug Profile 226 serelaxin - Drug Profile 227 serpinin - Drug Profile 230 SG-1002 - Drug Profile 231 sildenafil citrate - Drug Profile 233 Small Molecule to Inhibit BMP for Cardiovascular, CNS, Oncology and Musculoskeletal Disorders - Drug Profile 235 Small Molecule to Inhibit NOX-4 for Heart Failure - Drug Profile 236 Small Molecule to Inhibit ROMK for Hypertension and Heart Failure - Drug Profile 237 Small Molecules for Chronic Heart Failure - Drug Profile 238 Small Molecules for Diabetes and Congestive Heart Failure - Drug Profile 239 Small Molecules to Activate RXFP1 for Heart Failure and Fibrosis - Drug Profile 240 Small Molecules to Inhibit CaMKII for Arrhythmias and Heart Failure - Drug Profile 241 Small molecules to Inhibit CYP11B2 for Cardiovascular Diseases - Drug Profile 242 Small Molecules to Inhibit G betagamma for Heart Failure, Hypertension, Inflammation and Pain - Drug Profile 243 Small Molecules to Inhibit PDE4 for Heart Failure - Drug Profile 244 Small Molecules to Inhibit PDE5 for Cardiovascular Disease - Drug Profile 245 Small Molecules to Inversely Agonize Beta3-Adrenoreceptor for Cachexia, Heart Failure and Metabolic Syndrome - Drug Profile 246 Small Molecules to Taregt Beta 2 Adrenergic Receptor and Cannabinoid Receptor for Oncology, Respiratory and Cardiovascular Disorders - Drug Profile 247 sodium nitrite - Drug Profile 248 SP-20202 - Drug Profile 250 Stem Cell Therapy for Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease, Infectious Disease and Toxicology - Drug Profile 251 Stem Cell Therapy for Heart failure - Drug Profile 253 Stem Cell Therapy for Heart Failure - Drug Profile 254 Stem Cell Therapy for Multiple Sclerosis, Rheumatoid Arthritis, Osteoarthritis, Autism, Bronchopulmonary Dysplasia, Heart Failure and Cerebral Palsy - Drug Profile 255 Stem Cell Therapy for Myocardial Infarction and Heart Failure - Drug Profile 257 Synthetic Peptide to Activate Erythropoietin Receptor for Cardiovascular Diseases - Drug Profile 258 TD-0714 - Drug Profile 259 TR-4 - Drug Profile 260 TRC-4186 - Drug Profile 261 TRV-027 - Drug Profile 263 TRV-120023 - Drug Profile 265 ularitide - Drug Profile 266 vepoloxamer - Drug Profile 267 vericiguat - Drug Profile 269 XC-002 - Drug Profile 270 Xcel-hCardP - Drug Profile 271 XEN-105 - Drug Profile 272 Congestive Heart Failure (Heart Failure) - Recent Pipeline Updates 273 Congestive Heart Failure (Heart Failure) - Dormant Projects 367 Congestive Heart Failure (Heart Failure) - Discontinued Products 377 Congestive Heart Failure (Heart Failure) - Product Development Milestones 379 Featured News & Press Releases 379 Appendix 387 Methodology 387 Coverage 387 Secondary Research 387 Primary Research 387 Expert Panel Validation 387 Contact Us 387 Disclaimer 388
List of Tables
Number of Products under Development for Congestive Heart Failure (Heart Failure), H1 2016 21 Number of Products under Development for Congestive Heart Failure (Heart Failure) - Comparative Analysis, H1 2016 22 Number of Products under Development by Companies, H1 2016 24 Number of Products under Development by Companies, H1 2016 (Contd..1) 25 Number of Products under Development by Companies, H1 2016 (Contd..2) 26 Number of Products under Development by Companies, H1 2016 (Contd..3) 27 Number of Products under Development by Companies, H1 2016 (Contd..4) 28 Number of Products under Investigation by Universities/Institutes, H1 2016 29 Comparative Analysis by Late Stage Development, H1 2016 30 Comparative Analysis by Clinical Stage Development, H1 2016 31 Comparative Analysis by Early Stage Development, H1 2016 32 Comparative Analysis by Unknown Stage Development, H1 2016 33 Products under Development by Companies, H1 2016 34 Products under Development by Companies, H1 2016 (Contd..1) 35 Products under Development by Companies, H1 2016 (Contd..2) 36 Products under Development by Companies, H1 2016 (Contd..3) 37 Products under Development by Companies, H1 2016 (Contd..4) 38 Products under Development by Companies, H1 2016 (Contd..5) 39 Products under Development by Companies, H1 2016 (Contd..6) 40 Products under Investigation by Universities/Institutes, H1 2016 41 Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 42 Congestive Heart Failure (Heart Failure) - Pipeline by Amgen Inc., H1 2016 43 Congestive Heart Failure (Heart Failure) - Pipeline by AnGes MG, Inc., H1 2016 44 Congestive Heart Failure (Heart Failure) - Pipeline by Angion Biomedica Corp., H1 2016 45 Congestive Heart Failure (Heart Failure) - Pipeline by ARCA biopharma, Inc., H1 2016 46 Congestive Heart Failure (Heart Failure) - Pipeline by Ascelegen Therapeutics, Inc., H1 2016 47 Congestive Heart Failure (Heart Failure) - Pipeline by Asklepios BioPharmaceutical, Inc., H1 2016 48 Congestive Heart Failure (Heart Failure) - Pipeline by Asterias Biotherapeutics, Inc., H1 2016 49 Congestive Heart Failure (Heart Failure) - Pipeline by Athersys, Inc., H1 2016 50 Congestive Heart Failure (Heart Failure) - Pipeline by Bayer AG, H1 2016 51 Congestive Heart Failure (Heart Failure) - Pipeline by BEAT BioTherapeutics Corp., H1 2016 52 Congestive Heart Failure (Heart Failure) - Pipeline by BioCardia, Inc., H1 2016 53 Congestive Heart Failure (Heart Failure) - Pipeline by Bristol-Myers Squibb Company, H1 2016 54 Congestive Heart Failure (Heart Failure) - Pipeline by Capricor Therapeutics, Inc., H1 2016 55 Congestive Heart Failure (Heart Failure) - Pipeline by Celyad SA, H1 2016 56 Congestive Heart Failure (Heart Failure) - Pipeline by FibroGen, Inc., H1 2016 57 Congestive Heart Failure (Heart Failure) - Pipeline by GlaxoSmithKline Plc, H1 2016 58 Congestive Heart Failure (Heart Failure) - Pipeline by Glucox Biotech AB, H1 2016 59 Congestive Heart Failure (Heart Failure) - Pipeline by Heart Metabolics Limited, H1 2016 60 Congestive Heart Failure (Heart Failure) - Pipeline by Hemostemix Ltd, H1 2016 61 Congestive Heart Failure (Heart Failure) - Pipeline by Innopharmax Inc., H1 2016 62 Congestive Heart Failure (Heart Failure) - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H1 2016 63 Congestive Heart Failure (Heart Failure) - Pipeline by Juventas Therapeutics, Inc., H1 2016 64 Congestive Heart Failure (Heart Failure) - Pipeline by La Jolla Pharmaceutical Company, H1 2016 65 Congestive Heart Failure (Heart Failure) - Pipeline by Laboratoires Pierre Fabre SA, H1 2016 66 Congestive Heart Failure (Heart Failure) - Pipeline by Lee's Pharmaceutical Holdings Limited, H1 2016 67 Congestive Heart Failure (Heart Failure) - Pipeline by Les Laboratoires Servier SAS, H1 2016 68 Congestive Heart Failure (Heart Failure) - Pipeline by Lonestar Heart, Inc., H1 2016 69 Congestive Heart Failure (Heart Failure) - Pipeline by Mast Therapeutics, Inc., H1 2016 70 Congestive Heart Failure (Heart Failure) - Pipeline by Merck & Co., Inc., H1 2016 71 Congestive Heart Failure (Heart Failure) - Pipeline by Mesoblast Limited, H1 2016 72 Congestive Heart Failure (Heart Failure) - Pipeline by MI.TO. Technology S.r.L., H1 2016 73 Congestive Heart Failure (Heart Failure) - Pipeline by miRagen Therapeutics, Inc., H1 2016 74 Congestive Heart Failure (Heart Failure) - Pipeline by Novartis AG, H1 2016 75 Congestive Heart Failure (Heart Failure) - Pipeline by Nuo Therapeutics, Inc., H1 2016 76 Congestive Heart Failure (Heart Failure) - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016 77 Congestive Heart Failure (Heart Failure) - Pipeline by Palatin Technologies, Inc., H1 2016 78 Congestive Heart Failure (Heart Failure) - Pipeline by Pfizer Inc., H1 2016 79 Congestive Heart Failure (Heart Failure) - Pipeline by PharmaIN Corporation, H1 2016 80 Congestive Heart Failure (Heart Failure) - Pipeline by PhaseBio Pharmaceuticals, Inc., H1 2016 81 Congestive Heart Failure (Heart Failure) - Pipeline by Pluristem Therapeutics Inc., H1 2016 82 Congestive Heart Failure (Heart Failure) - Pipeline by Quantum Genomics SA, H1 2016 83 Congestive Heart Failure (Heart Failure) - Pipeline by Recardio GmbH, H1 2016 84 Congestive Heart Failure (Heart Failure) - Pipeline by RedHill Biopharma Ltd., H1 2016 85 Congestive Heart Failure (Heart Failure) - Pipeline by Sanofi, H1 2016 86 Congestive Heart Failure (Heart Failure) - Pipeline by Stealth BioTherapeutics Inc., H1 2016 87 Congestive Heart Failure (Heart Failure) - Pipeline by Stemedica Cell Technologies, Inc., H1 2016 88 Congestive Heart Failure (Heart Failure) - Pipeline by Target Heart Biotec Srl, H1 2016 89 Congestive Heart Failure (Heart Failure) - Pipeline by Theravance Biopharma, Inc., H1 2016 90 Congestive Heart Failure (Heart Failure) - Pipeline by TiGenix NV, H1 2016 91 Congestive Heart Failure (Heart Failure) - Pipeline by Torrent Pharmaceuticals Limited, H1 2016 92 Congestive Heart Failure (Heart Failure) - Pipeline by Trevena, Inc., H1 2016 93 Congestive Heart Failure (Heart Failure) - Pipeline by U.S. Stem Cell, Inc., H1 2016 94 Congestive Heart Failure (Heart Failure) - Pipeline by UniQure N.V., H1 2016 95 Congestive Heart Failure (Heart Failure) - Pipeline by Vichem Chemie Research Ltd., H1 2016 96 Congestive Heart Failure (Heart Failure) - Pipeline by Vicore Pharma AB, H1 2016 97 Congestive Heart Failure (Heart Failure) - Pipeline by Zensun (Shanghai) Sci & Tech Co., Ltd., H1 2016 98 Assessment by Monotherapy Products, H1 2016 99 Assessment by Combination Products, H1 2016 100 Number of Products by Stage and Target, H1 2016 102 Number of Products by Stage and Mechanism of Action, H1 2016 107 Number of Products by Stage and Route of Administration, H1 2016 111 Number of Products by Stage and Molecule Type, H1 2016 113 Congestive Heart Failure (Heart Failure) Therapeutics - Recent Pipeline Updates, H1 2016 282 Congestive Heart Failure (Heart Failure) - Dormant Projects, H1 2016 376 Congestive Heart Failure (Heart Failure) - Dormant Projects (Contd..1), H1 2016 377 Congestive Heart Failure (Heart Failure) - Dormant Projects (Contd..2), H1 2016 378 Congestive Heart Failure (Heart Failure) - Dormant Projects (Contd..3), H1 2016 379 Congestive Heart Failure (Heart Failure) - Dormant Projects (Contd..4), H1 2016 380 Congestive Heart Failure (Heart Failure) - Dormant Projects (Contd..5), H1 2016 381 Congestive Heart Failure (Heart Failure) - Dormant Projects (Contd..6), H1 2016 382 Congestive Heart Failure (Heart Failure) - Dormant Projects (Contd..7), H1 2016 383 Congestive Heart Failure (Heart Failure) - Dormant Projects (Contd..8), H1 2016 384 Congestive Heart Failure (Heart Failure) - Dormant Projects (Contd..9), H1 2016 385 Congestive Heart Failure (Heart Failure) - Discontinued Products, H1 2016 386 Congestive Heart Failure (Heart Failure) - Discontinued Products (Contd..1), H1 2016 387


List of Figures
Number of Products under Development for Congestive Heart Failure (Heart Failure), H1 2016 21 Number of Products under Development for Congestive Heart Failure (Heart Failure) - Comparative Analysis, H1 2016 22 Number of Products under Development by Companies, H1 2016 23 Number of Products under Investigation by Universities/Institutes, H1 2016 29 Comparative Analysis by Late Stage Development, H1 2016 30 Comparative Analysis by Clinical Stage Development, H1 2016 31 Comparative Analysis by Early Stage Products, H1 2016 32 Assessment by Monotherapy Products, H1 2016 99 Assessment by Combination Products, H1 2016 100 Number of Products by Top 10 Targets, H1 2016 101 Number of Products by Stage and Top 10 Targets, H1 2016 101 Number of Products by Top 10 Mechanism of Actions, H1 2016 106 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 106 Number of Products by Top 10 Routes of Administration, H1 2016 110 Number of Products by Stage and Top 10 Routes of Administration, H1 2016 110 Number of Products by Top 10 Molecule Types, H1 2016 112 Number of Products by Stage and Top 10 Molecule Types, H1 2016 112

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global lignin market size is expected to exceed USD 6 billion by 2022, growing at 4.9% from 2015 to 2022. Rising demand for animal feed and potential as a feedstock substitute to crude oil are expected to drive lignin market demand over the forecast

Read More...

Global Automated Test Equipment (ATE) market is expected to be valued at USD 4.48 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing design complexity coupled with need for effective testing is expected to drive the gl

Read More...

Global gold nanoparticles market size is expected to reach 4.99 billion by 2020, witnessing gains at a CAGR of 24.7%. Positive outlook towards the increasing applications of nanotechnology in medical and dentistry such as drug delivery systems, nanom

Read More...

Global advanced energy storage systems market size is anticipated to be valued at USD 24.8 billion by 2022, as per a new research report by Radiant Insights, Inc. Increasing energy consumption coupled with strong energy demand for industrial, commerc

Read More...

Global gas sensors market is expected to reach USD 2,512.4 million by 2020, as per a new research report by Radiant Insights, Inc. High adoption rate of wireless and smart gas sensor technology coupled with escalating demand from end-use industries s

Read More...
Choose License Type
Single User - US $2000
Multi User - US $4000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify